Trial
NCT05473715
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bayer
Collaborators
—
Condition
Neovascular (Wet) Age-related Macular Degeneration
Intervention
Aflibercept(BAY86-5321, Eylea)
Why stopped
Study terminated due to administrative reasons not related to efficacy or safety.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-16